Attenuation of scopolamine-induced deficits in delayed-matching performance by a new muscarinic agonist

Psychobiology

Volumn 25, Issue 4, 1997, Pages 313-320

  Ruske, Angela C ^a   Fisher, A ^b   White, K Geoffrey ^a  

^a UNIVERSITY OF OTAGO   (New Zealand)

^b ISRAEL INSTITUTE FOR BIOLOGICAL RESEARCH   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

1 METHYLPIPERIDINE 4 SPIRO (2' METHYLTHIAZOLINE); AF 150S; AF 151S; MUSCARINIC M1 RECEPTOR AGONIST; SCOPOLAMINE; UNCLASSIFIED DRUG;

ALZHEIMER DISEASE; AMNESIA; ANIMAL EXPERIMENT; ARTICLE; ATTENUATION; CHOLINERGIC SYSTEM; COGNITIVE DEFECT; CONTROLLED STUDY; DOSE RESPONSE; INTRAPERITONEAL DRUG ADMINISTRATION; NONHUMAN; PERCEPTIVE DISCRIMINATION; PIGEON; TASK PERFORMANCE;

EID: 0031425062     PISSN: 08896313     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (45)

1. BARTUS, R. T. (1978). Evidence for a direct cholinergic involvement in the scopolamine-induced amnesia in monkeys: Effects of concurrent administration of physostigmine and methylphenidate with scopolamine. Pharmacology, Biochemistry & Behavior, 9, 833-836.
2. BARTUS, R. T., DEAN, R. L., BEER, B., & LIPPA, A. S. (1982). The cholinergic hypothesis of geriatric memory dysfunction. Science, 217, 408-417.
3. BEERMANN, B. (1993). Side effects of long acting cholinesterase inhibitors. Acta Neurologica Scandinavica, 88 (Suppl. 149), 53-54.
4. BRANDEIS, R., DACHIR, S., SAPIR, M., LEVY, A., & FISHER, A. (1990). Reversal of age-related cognitive impairments by an M1 cholinergic agonist, AF102B. Pharmacology, Biochemistry & Behavior, 36, 89-95.
5. BRANDEIS, R., SAPIR, M., HAFIF, N., ABRAHAM, S., OZ, N., STEIN, E., & FISHER, A. (1995). AF150(S): A new functionally selective M1 agonist improves cognitive performance in rats. Pharmacology, Biochemistry & Behavior, 51, 667-674.
6. BYMASTER, F. P., HEATH, I., HENDRIX, J. C., & SHANNON, H. E. (1993). Comparative behavioral and neurochemical activities of cholinergic antagonists in rats. Journal of Pharmacology & Experimental Therapeutics, 267, 16-24.
7. COYLE, J. T., PRICE, D. L., & DELONG, M. R. (1983). Alzheimer's disease: A disorder of cortical cholinergic innervation. Science, 219, 1184-1190.
8. DAVIS, R., RABY, C., CALLAHAN, M. J., LIPINSKI, W., SCHWARZ, R., DUDLEY, D. T., LAUFFER, D., REECE, P., JAEN, J., & TECLE, H. (1993). Subtype selective muscarinic agonists: Potential therapeutic agents for Alzheimer's disease. Progress in Brain Research, 98, 439-445.
9. DRACHMAN, D. A. (1977). Memory and cognitive function in man: Does the cholinergic system have a specific role? Neurology, 27, 783-790.
10. DRACHMAN, D. A., & LEAVITT, J. L. (1974). Human memory and the cholinergic system. A relationship to aging? Archives of Neurology, 30, 113-121.
11. DUNNETT, S. B. (1985). Comparative effects of cholinergic drugs and lesions of nucleus basalis or fimbria-fornix on delayed matching in rats. Psychopharmacology, 87, 357-363.
12. EBERT, U., RAMEZANI, E., WESNES, K. A., & KIRCH, W. (1997). The dose-dependent, but temporary, ability of physostigmine to counteract the effects of scopolamine on cognitive function in young volunteers. Proceedings of the British Psychology Society, 5, 48.
13. FISHER, A., BRANDEIS, R., KARTON, I., PITTEL, Z., GURWITZ, D., HARING, R., SAPIR, M., LEVY, A., & HELDMAN, E. (1991). (±)-cis-2-Methyl-spiro(1,3-oxathiolane-5,3′)quinuclidine, an M1 selective cholinergic agonist, attenuates cognitive dysfunctions in an animal model of Alzheimer's disease. Journal of Pharmacology & Experimental Therapeutics, 257, 392-403.
14. FISHER, A., BRANDEIS, R., PITTEL, Z., KARTON, I., SAPIR, M., DACHIR, S., LEVY, A., & HELDMAN, E. (1989). (±)-cis-2-Methyl-spiro(1,3-oxathiolane-5,3′)quinuclidine (AF102B): A new M1 agonist attenuates cognitive dysfunctions in AF64A-treated rats. Neuroscience Letters, 102, 325-331.
15. FISHER, A., HELDMAN, E., GURWITZ, D., HARING, R., MESHULAM, H., BRANDEIS, R., SAPIR, M., MARCIANNO, D., BARAK, D., VOGEL, Z., & KARTON, Y. (1993). AF150(S) and AF151(S): New Ml agonists mediate m1 selective signalling, neurotrophic-like effects and restore AF64A cognitive deficits in rats. Society for Neuroscience Abstracts, 19, 1767.
16. GLICK, S. D., & JARVIK, M. E. (1970). Differential effects of amphetamine and scopolamine upon matching performance of monkeys with lateral frontal lesions. Journal of Comparative Physiological Psychology, 73, 307-313.
17. HAUTUS, M. J. (1995). Corrections for extreme proportions and their biasing effects on estimated values of d′. Behavioral Research Methods, Instruments, & Computers, 27, 46-51.
18. HOLLANDER, E., DAVIDSON, M., MOHS, R. C., HORVATH, T. B., DAVIS, B. M., ZEMISHLANY, Z., & DAVIS, K. L. (1987). RS 86 in the treatment of Alzheimer's disease: Cognitive and biological effects. Biological Psychiatry, 22, 1067-1078.
19. HOLLANDER, E., MOHS, R. C., & DAVIS, K. L. (1986). Cholinergic approaches to the treatment of Alzheimer's disease. British Medical Bulletin, 42, 97-100.
20. KIRK, R. C., WHITE, K. G., & MCNAUGHTON, N. (1988). Low dose scopolamine affects discriminability but not rate of forgetting in delayed conditional discrimination. Psychopharmacology, 96, 541-546.
21. KOPELMAN, M. D. (1985). Rate of forgetting in Alzheimer-type dementia and Korsakoff's syndrome. Neuropsychologia, 23, 623-638.
22. LANGE, K. W., SAHAKIN, B. J., QUINN, N. P., MARSDEN, C. D., & ROBBINS, T. W. (1995). Comparison of executive and visuospatial memory function in Huntington's disease and dementia of Alzheimer type matched for degree of dementia. Journal of Neurology, Neurosurgery & Psychiatry, 58, 598-606.
23. MASH, D. C., FLYNN, D. D., & POTTER, L. T. (1985). Loss of M2 muscarinic receptors in the cerebral cortex in Alzheimer's disease and experimental cholinergic denervation. Science, 228, 115-117.
24. MEDINA, L., & REINER, A. (1994). Distribution of choline acetyltransferase immunoreactivity in the pigeon brain. Journal of Comparative Neurology, 342, 497-537.
25. MONEY, E. A., KIRK, R. C., & MCNAUGHTON, N. (1992). Alzheimer's dementia produces a loss of discrimination but no increase in rate of memory decay in delayed matching to sample. Neuropsychologia, 30, 133-143.
26. ONO, S., SAITO, Y., OHGANE, N., KAWANISHI, G., & MIZOBE, F. (1988). Heterogeneity of muscarinic autoreceptors and heteroreceptors in the rat brain: Effects of a novel M1 agonist, AF102B. European Journal of Pharmacology, 155, 77-84.
27. PENETAR, D. M., & MCDONOUGH, J. H. (1983). Effects of cholinergic drugs on delayed matching-to-sample performance of rhesus monkeys. Pharmacology, Biochemistry & Behavior, 19, 963-967.
28. PERRY, E. K. (1986). The cholinergic-hypothesis - Ten years on. British Medical Bulletin, 42, 63-69.
29. PERRY, E. K., TOMLINSON, B. E., BLESSED, G., BERGMANN, K., GIBSON, P., & PERRY, R. H. (1978). Correlation of cholinergic abnormalities with senile plaques and mental test scores in dementia. British Medical Journal, 2, 1457-1459.
30. PETERSEN, R. C. (1977). Scopolamine induced learning failures in man. Psychopharmacology, 52, 283-289.
31. PETERSON, L. R., & PETERSON, M. (1959). Short-term retention of individual items. Journal of Experimental Psychology, 58, 193-198.
32. SAFER, D. J., & ALLEN, R. P. (1971). The central effects of scopolamine in man. Biological Psychiatry, 3, 347-355.
33. SAHGAL, A., GALLOWAY, P. H., MCKEITH, I. G., LLOYD, S., COOK, J. H., FERRIER, I. N., & EDWARDSON, J. A. (1992). Matching to sample deficits in patients with senile dementias of the Alzheimer and Lewy body types. Archives of Neurology, 49, 1043-1046.
34. SAVAGE, L. M., STANCHFIELD, M. A., & OVERMIER, J. B. (1994). The effects of scopolamine, diazepam, and lorazepam on working memory in pigeons: An analysis of reinforcement procedures and sample problem type. Pharmacology, Biochemistry & Behavior, 48, 183-191.
35. SHIMIZU, T., & KARTEN, H. J. (1990). Immunohistochemical analysis of the visual wulst of the pigeons (Columba livia). Journal of Comparative Neurology, 300, 346-369.
36. 125I-alpha-bungarotoxin binding to nicotinic site in the chicken forebrain and midbrain. Journal of Comparative Neurology, 323, 1-12.
37. TEAL, J. J., & EVANS, H. L. (1982). Effects of DDAVP, a vasopressin analog, on delayed matching behavior in the pigeon. Pharmacology, Biochemistry & Behavior, 17, 1123-1127.
38. VOLGER, B. W. (1991). Alternatives in the treatment of memory loss in patients with Alzheimer's disease. Clinical Pharmacy, 10, 447-450.
39. WATSON, J. E., & BLAMPIED, N. M. (1989). Quantification of the effects of chlorpromazine on performance under delayed matching to sample in pigeons. Journal of Experimental Analysis of Behavior, 51, 317-328.
40. WENGER, G. R., HUDZIK, T. J., & WRIGHT, D. W. (1993). Titrating matching-to-sample performance in pigeons: Effects of diazepam, morphine, and cholinergic agents. Pharmacology, Biochemistry & Behavior, 46, 435-443.
41. WHITE, K. G. (1985). Characteristics of forgetting functions. Journal of the Experimental Analysis of Behavior, 44, 15-34.
42. WHITE, K. G., & HARPER, D. N. (1996). Quantitative reanalysis of lesion effects on rate of forgetting in macaques. Behavioural Brain Research, 74, 223-227.
43. WHITE, K. G., HARPER, D. N., & WATSON, J. E. (1994). Effects of chronic phenobarbital administration on forgetting functions in pigeons. Pharmacology, Biochemistry & Behavior, 49, 427-431.
44. WHITE, K. G., RUSKE, A. C., & COLOMBO, M. (1996). Memory procedures, performance, and processes in pigeons. Cognitive Brain Research, 3, 309-317.
45. WHITEHOUSE, P. J. (1986). Neuronal loss and neurotransmitter receptor alterations in Alzheimer's disease. In A. Fisher, I. Hanin, & C. Lachman (Eds.), Alzheimer's and Parkinson's disease: Strategies for research and development (pp. 185-94). New York: Plenum.